Anti-Human Coagulation factor III/Tissue Factor Reference Antibody (EDO-B278, RUO) (HB058066)

Name: Anti-Human Coagulation factor III/Tissue Factor Reference Antibody (EDO-B278, RUO)
Brand: abinScience
SKU: HB058066
Price: 326 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HB058066
Descripción	Anti-Human CD142/F3/TF (EDO-B278) (HB058066) is a research-grade recombinant antibody targeting CD142. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	EDO-B278
Sistema de expresión	Mammalian cells
Objetivo	Tissue factor, CD142, F3, Thromboplastin, Coagulation factor III, TF
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P13726
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	EDO-B278, EDOB278, EDOB278
Fondo	Tissue factor (CD142/F3) is a ~33 kDa protein. Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade. CD142 is the therapeutic target of tisotumab vedotin (Tivdak).
Nota	For research use only. Not suitable for clinical or therapeutic use.